Hugo Hensley

Articles by Hugo Hensley

Hugo Hensley

Parental Control: Why Pharma’s Strongest Asset May Be Its Parent Brand

January 5th 2026

Latest Updated Articles

Trending on PharmExec

Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909

Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics

New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report

Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data

FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy